Summary of SLU-PP-332 (EVOLVE) · Peptide Resource Center

Summary of SLU-PP-332 (EVOLVE)

❇️ SLU-PP-332, often referred to as EVOLVE, is an experimental PPARδ (Peroxisome Proliferator-Activated Receptor delta) agonist. It has gained interest for its ability to enhance endurance, improve fat metabolism, and support muscle preservation without the need for intense training.

By activating PPARδ, SLU-PP-332 shifts the body’s metabolism toward greater fat oxidation, increased aerobic capacity, and improved muscle efficiency. This makes it a candidate for research in exercise mimetics, metabolic disorders, obesity, and endurance enhancement.

❇️ SLU-PP-332 (EVOLVE) – FAQs

Q: Is SLU-PP-332 similar to GW-501516 (Cardarine)?

A: Yes – both are PPARδ agonists, but SLU-PP-332 is being studied as a next-generation, potentially safer version.

Q: Does SLU-PP-332 build muscle?

A: Indirectly – it helps preserve lean muscle and enhances endurance, but it is not primarily an anabolic peptide.

Q: How quickly does it work?

A: Endurance and fat metabolism improvements may appear within 1–2 weeks of research use.

Q: Can it be stacked with other peptides?

A: In research settings, it may be combined with fat loss or endurance peptides (e.g., AOD-9604, CJC-1295/Ipamorelin) for synergistic effects.

❇️ SLU-PP-332 (EVOLVE) - Key Information

Type: Experimental PPARδ agonist (exercise mimetic)

⚙️ Mechanism of Action:

Activates PPARδ receptors in muscle and metabolic tissues
Increases fatty acid oxidation and shifts energy use from glucose to fat
Enhances aerobic endurance capacity (“exercise without exercise” effect)
Preserves lean muscle mass while promoting fat loss

🧬 Primary Research & Potential Uses

Endurance enhancement (aerobic performance research)
Fat loss and obesity studies
Metabolic syndrome and insulin resistance research
Muscle preservation in aging or catabolic conditions
Potential application as an exercise mimetic for those unable to train intensively

⚡️ Onset of Action

Gradual – metabolic effects may build over 1–2 weeks of research use

Half-life:

Experimental data suggest moderate (hours), requiring consistent dosing

Regulation:

Research compound (not FDA-approved; experimental only)

❇️ Reported Benefits (research/experimental reports)

Positive:

Increased endurance capacity without additional training
Improved fat burning and weight management
Preservation of lean muscle during calorie restriction
Potential improvement in metabolic flexibility

Neutral/Negative:

Effects more noticeable in endurance and fat metabolism, less in strength gains
Still highly experimental – limited human data

❇️ What experiences have SLU-PP-332 (EVOLVE) users had?

➡ Positive:

May improve joint comfort and mobility
Potential regenerative effect on cartilage
Supports reduction of inflammation in arthritic models
May help in slowing age-related cartilage breakdown

➡ Neutral/Negative:

Results vary depending on joint condition severity
Requires consistent use in cycles for best effect
Not a cure for advanced degenerative disease

⚠️ Dependency Risk

Low risk – does not act on addictive pathways
Works by cellular modulation, not by masking pain like NSAIDs

💉 Dosage

Standard vial: 5 mg
Typical research dosing: Still under study; often referenced in the 5–15 mg/day range in experimental reports
Administration: Oral (capsule/reconstituted solution)
Cycle length: Often tested in short cycles (4–8 weeks)

⚠️ Side Effects

Common (reported in research):